Lonafarnib

  • TRADE NAMES: SCH 663366; Zokinvy (Eiger Biopharmaceuticals)
  • INDICATIONS:

    Reduction of the risk of mortality in Hutchinson-Gilford Progeria Syndrome. For treatment of processing-deficient Progeroid Laminopathies with either heterozygous LMNA mutation with progerin-like protein accumulation or homozygous or compound heterozygous ZMPSTE24 mutations.


  • CLASS: Farnesyltransferase inhibitor
  • HALF-LIFE: approximately 4–6 hours

FDA APPROVAL DATE: 11/20/2020

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Atorvastatin, CYP2C9 inhibitors, CYP3A inducers, CYP3A inhibitors, Grapefruit Juice, Loperamide, Lovastatin, Midazolam, Simvastatin


Can cause fetal harm. Advise females of reproductive potential of the risk to a fetus and to use effective contraception.

Based on animal studies, may impair fertility. Advise females and males of the adverse reproductive potential of lonafarnib.

Our database has 31 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RESPIRATORY.
OTHER.


Page last updated 07/05/2021

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top